Adalimumab biosimilar (Shilpa Biologicals)

阿达木单抗生物类似药（Shilpa Biologicals）

Report date: 2024/08/21 14:09:32

Base Information

Drug NameAdalimumab biosimilar (Shilpa Biologicals)
Drug Alias NameSBDM-02
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisPolyarticular Juvenile Idiopathic ArthritisCrohn Disease +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesShilpa Biologicals Pvt Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShilpa Biologicals Pvt Ltd
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPolyarticular Juvenile Idiopathic ArthritisCrohn Disease +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A